Invasive fungal infections: Epidemiology and analysis of antifungal prescriptions in onco-haematology

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 2, 2011, Pages 152-160

  Des Champs Bro, B ^a   Leroy Cotteau, A ^a   Mazingue, F ^b   Pasquier, F ^c   Francois N ^d   Corm, S ^c   Lemaitre, L ^e   Poulain, D ^d   Yakoub Agha, I ^c   Alfandari, S ^d   Sendid, B ^d  

^a Pharmacy Department   (France)

^b Pediatric Oncology Department   (France)

^c Haematology Department   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e Radiology Department   (France)

Author keywords

antifungals; epidemiology; invasive fungal diseases; onco haematology

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ACUTE LEUKEMIA; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; DRUG COST; DRUG UTILIZATION; ECONOMIC ASPECT; HEALTH SURVEY; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LUNG ASPERGILLOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; MUCORMYCOSIS; NEPHROTOXICITY; NEUTROPENIA; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; SYSTEMIC MYCOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; ANTIFUNGAL AGENTS; CHILD; DISEASE PROGRESSION; HEMATOLOGIC NEOPLASMS; HUMANS; MYCOSES; NEUTROPENIA; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79952253717     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01166.x     Document Type: Article

References (41)

1. Eggimann P, Garbino J, Pittet D, (2003) Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infectious Diseases, 3, 685-702. (Pubitemid 37345347)
2. Safdar A, Armstrong D, (2002) Prospective evaluation of Candida species colonization in hospitalized cancer patients: impact on short-term survival in recipients of marrow transplantation and patients with hematological malignancies. Bone Marrow Transplantation, 30, 931-935. (Pubitemid 36097483)
3. Fridkin SK, Jarvis WR, (1996) Epidemiology of nosocomial fungal infections. Clinical Microbiology Reviews, 9, 499-511. (Pubitemid 26366535)
4. Denning DW, (1996) Therapeutic outcome in invasive aspergillosis. Clinical Infectious Diseases, 23, 608-615. (Pubitemid 26304513)
5. Meunier F, Lukan C, (2008) The First European Conference on Infections in Leukaemia-ECIL1: A current perspective. European Journal of Cancer, 44, 2112-2117.
6. Kontoyiannis DP, (2001) A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America Pharmacotherapy, 21, 175S-187S. (Pubitemid 32727044)
7. Rex JH, Walsh TJ, Sobel JD, et al. (2000) Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America Clinical Infectious Diseases, 30, 662-678.
8. Stevens DA, Kan VL, Judson MA, et al. (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America Clinical Infectious Diseases, 30, 696-709.
9. Alfandari S, Leroy O, de Botton S, et al. (2005) [Management of aspergillosis in immunocompromised patients. Recommendations of Lille University Hospital. 4th version. November 2004]. Médecine et Maladies Infectieuses, 35, 121-134. (Pubitemid 40732074)
10. De Pauw B, Walsh TJ, Donnelly JP, et al. (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 46, 1813-1821.
11. Herbrecht R, Denning DW, Patterson TF, et al. (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine, 347, 408-415. (Pubitemid 34851833)
12. McNeil MM, Nash SL, Hajjeh RA, et al. (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clinical Infectious Diseases, 33, 641-647. (Pubitemid 32762937)
13. Denning DW, Marinus A, Cohen J, et al. (1998) An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. Journal of Infection, 37, 173-180. (Pubitemid 28482922)
14. Martino R, Subira M, Rovira M, et al. (2002) Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. British Journal of Haematology, 116, 475-482. (Pubitemid 34155525)
15. Muhlemann K, Wenger C, Zenhausern R, Tauber MG, (2005) Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia, 19, 545-550. (Pubitemid 40521158)
16. Pagano L, Caira M, Candoni A, et al. (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica, 91, 1068-1075. (Pubitemid 44208634)
17. Richet H, Roux P, Des Champs C, Esnault Y, Andremont A, (2002) Candidemia in French hospitals: incidence rates and characteristics. Clinical Microbiology Infection, 8, 405-412. (Pubitemid 34993817)
18. Tortorano AM, Peman J, Bernhardt H, et al. (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. European Journal of Clinical Microbiology and Infectious Diseases, 23, 317-322. (Pubitemid 38669942)
19. Eloy O, Blanc V, Pina P, et al. (2006) [Epidemiology of candidemia: results of a one month French hospitals-based surveillance study in 2004]. Pathology Biology (Paris), 54, 523-530. (Pubitemid 44716611)
20. Sendid B, Cotteau A, Francois N, et al. (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recommendations and Reports, 49, 1-125. CE1-CE7.
21. Sendid B, Cotteau A, Francois N, et al. (2006) Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infectious Diseases, 6, 80-88.
22. Tricot S, Gastine T, Sendid B, Wurtz A, de Botton S, Alfandari S, (2006) [Pulmonary zygomycosis in a patient treated for invasive aspergillosis]. Médecine et Maladies Infectieuses, 36, 118-121. (Pubitemid 43294634)
23. Prella M, Bille J, Pugnale M, et al. (2005) Early diagnosis of invasive candidiasis with mannan antigenemia and antimannan antibodies. Diagnostic Microbiology Infectious Diseases, 51, 95-101. (Pubitemid 40215418)
24. Pfeiffer CD, Fine JP, Safdar N, (2006) Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clinical Infectious Diseases, 42, 1417-1427.
25. Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van Der Schee C, Hoogsteden HC, De Marie S, (2003) Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. British Journal of Haematology, 121, 448-457. (Pubitemid 36628336)
26. Bow EJ, (2005) Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Medical Mycology, 43 (Suppl. 1), S277-S287. (Pubitemid 41038579)
27. Hamza NS, Ghannoum MA, Lazarus HM, (2004) Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 34, 377-389. (Pubitemid 39232366)
28. Siwek GT, Pfaller MA, Polgreen PM, et al. (2006) Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagnostic Microbiology Infectious Diseases, 55, 209-212. (Pubitemid 43928408)
29. Nucci M, Colombo AL, (2002) Emergence of resistant Candida in neutropenic patients. Brazilian Journal Infectious Diseases, 6, 124-128.
30. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. (2005) Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. Journal of Infectious Diseases, 191, 1350-1360.
31. Trifilio SM, Bennett CL, Yarnold PR, et al. (2007) Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplantation, 39, 425-429. (Pubitemid 46487308)
32. Pappas PG, Rex JH, Sobel JD, et al. (2004) Guidelines for treatment of candidiasis. Clinical Infectious Diseases, 38, 161-189. (Pubitemid 38113025)
33. Pappas PG, Rex JH, Sobel JD, et al. (1989) Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. The American Journal of Medicine, 86, 668-672.
34. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG, (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. American Journal of Medicine, 72, 101-111. (Pubitemid 12090793)
35. Le Guyader N, Tabone MD, Leverger G, (2007) [Antifungal therapy in children: new topics and prospects]. Archives of Paediatrics, 14, 1-3. (Pubitemid 46054458)
36. Cappelletty D, Eiselstein-McKitrick K, (2007) The echinocandins. Pharmacotherapy, 27, 369-388. (Pubitemid 46327905)
37. Perea S, Gonzalez G, Fothergill AW, Kirkpatrick WR, Rinaldi MG, Patterson TF, (2002) In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrobial Agents and Chemotherapy, 46, 3039-3041.
38. Schuster F, Moelter C, Schmid I, et al. (2005) Successful antifungal combination therapy with voriconazole and caspofungin. Pediatrics Blood and Cancer, 44, 682-685. (Pubitemid 40629222)
39. Klastersky J, Paesmans M, (2007) Antifungal therapy in febrile neutropenic patients: review of treatment choices and strategies for aspergillar infection. Supportive Care in Cancer, 15, 137-141. (Pubitemid 46332929)
40. Cordonnier C, (2007) Complications infectieuses des hémopathies. Hematologie, 13, 69-72.
41. de Pauw BE, Rubin RH, (2006) Empiric versus preemptive therapy in the management of febrile neutropenia in the patient being treated for hematologic malignancy. Transplant Infectious Disease, 8, 1-2.